Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug;83(2):237-279.
doi: 10.1016/j.jinf.2021.03.025. Epub 2021 Apr 1.

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

Marie Tré-Hardy  1 , Roberto Cupaiolo  2 , Emmanuelle Papleux  3 , Alain Wilmet  2 , Alexandra Horeanga  4 , Thomas Antoine-Moussiaux  4 , Andrea Della Vecchia  4 , Ingrid Beukinga  2 , Marc Vekemans  4 , Laurent Blairon  2
Affiliations
Comment

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

Marie Tré-Hardy et al. J Infect. 2021 Aug.
No abstract available

Keywords: COVID-19; Immunogenicity, Reactogenicity, Safety, mRNA-1273 vaccine; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no relevant competing interest to disclose in relation to this work.

Figures

Fig. 1:
Fig. 1
Antibody responses to one and two doses of the mRNA-1273 in seronegative and seropositive individuals.
Fig. 2:
Fig. 2
Reactogenicity and side effect profile of the mRNA-1273 in seronegative and seropositive individuals after the first and second doses.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021 doi: 10.1016/j.jinf.2021.03.015. - DOI - PMC - PubMed
    1. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021 doi: 10.1056/NEJMc2101667. - DOI - PMC - PubMed
    1. Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021 doi: 10.1016/S0140-6736(21)00501-8. - DOI - PMC - PubMed
    1. Tré-Hardy M, Wilmet A, Beukinga I, Dogné JM, Douxfils J, Blairon L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med. 2020;58(8):1357–1364. doi: 10.1515/cclm-2020-0594. - DOI - PubMed
    1. Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination programme for maximum short-term impact. 2021.